News
-
-
-
COMMUNIQUÉ DE PRESSE
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate. Study results confirm safety profile & effectiveness equal to standard care in reducing blood loss. Biotest aims to address global medical need with USD 800 million market potential -
-
COMMUNIQUÉ DE PRESSE
Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Biotest AG: Increase of the EBIT guidance
-
-
-
-